Mapping the Vif-A3G interaction using peptide arrays: a basis for anti-HIV lead peptides.
暂无分享,去创建一个
Robert Blumenthal | Jeeseong Hwang | Mathias Viard | Jeeseong Hwang | A. Friedler | R. Blumenthal | Shahar Rotem-Bamberger | M. Kotler | J. Y. Lee | Mathias Viard | Assaf Friedler | Ji Youn Lee | Amy Jacobs | Moshe Kotler | A. Jacobs | Shahar Rotem-Bamberger | Tali H Reingewertz | Elena Britan-Rosich | Abigail Miller | Tali H. Reingewertz | Elena Britan-Rosich | Abigail M. Miller | T. Reingewertz
[1] B. Schnierle,et al. HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G. , 2005, Current HIV research.
[2] M. Malim,et al. Identification of Amino Acid Residues in APOBEC3G Required for Regulation by Human Immunodeficiency Virus Type 1 Vif and Virion Encapsidation , 2007, Journal of Virology.
[3] S. Rüdiger,et al. Studying protein-protein interactions using peptide arrays. , 2011, Chemical Society reviews.
[4] B. Cullen,et al. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[5] Wolf Reik,et al. Mice Deficient in APOBEC2 and APOBEC3 , 2005, Molecular and Cellular Biology.
[6] Jared R. Auclair,et al. Mass spectrometry analysis of HIV‐1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity , 2007, Proteins.
[7] M. Malim,et al. RNA-Dependent Oligomerization of APOBEC3G Is Required for Restriction of HIV-1 , 2009, PLoS pathogens.
[8] Sylvie Rato,et al. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action. , 2007, Molecular immunology.
[9] S. Ikeda,et al. MDM2 is a novel E3 ligase for HIV-1 Vif , 2009, Retrovirology.
[10] B. Spire,et al. Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor , 1997, Journal of virology.
[11] H. Matsuo,et al. An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. , 2009, Journal of molecular biology.
[12] V. Pathak,et al. Identification of Two Distinct Human Immunodeficiency Virus Type 1 Vif Determinants Critical for Interactions with Human APOBEC3G and APOBEC3F , 2007, Journal of Virology.
[13] Hui Zhang,et al. Human Immunodeficiency Virus Type 1 Vif Protein Is an Integral Component of an mRNP Complex of Viral RNA and Could Be Involved in the Viral RNA Folding and Packaging Process , 2000, Journal of Virology.
[14] M. Malim,et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.
[15] H. Benyamini,et al. The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state. , 2009, Protein engineering, design & selection : PEDS.
[16] H. Matsuo,et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G , 2008, Nature.
[17] T. Rana,et al. Analysis of HIV-1 Viral Infectivity Factor-mediated Proteasome-dependent Depletion of APOBEC3G , 2005, Journal of Biological Chemistry.
[18] J. Goncalves,et al. Phosphorylation of Vif and Its Role in HIV-1 Replication (*) , 1996, The Journal of Biological Chemistry.
[19] S. Bernacchi,et al. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation , 2009, Nucleic acids research.
[20] M. Llano,et al. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. , 2004, Virology.
[21] Xiaojun Wang,et al. Identification of a Novel WxSLVK Motif in the N Terminus of Human Immunodeficiency Virus and Simian Immunodeficiency Virus Vif That Is Critical for APOBEC3G and APOBEC3F Neutralization , 2009, Journal of Virology.
[22] Reuben S Harris,et al. The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G , 2003, Current Biology.
[23] Xiao-Fang Yu,et al. A Patch of Positively Charged Amino Acids Surrounding the Human Immunodeficiency Virus Type 1 Vif SLVx4Yx9Y Motif Influences Its Interaction with APOBEC3G , 2009, Journal of Virology.
[24] M. Khan,et al. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. , 2003 .
[25] A. Telenti,et al. Model Structure of Human APOBEC3G , 2007, PloS one.
[26] Keyang Chen,et al. Virion-associated Uracil DNA Glycosylase-2 and Apurinic/Apyrimidinic Endonuclease Are Involved in the Degradation of APOBEC3G-edited Nascent HIV-1 DNA* , 2007, Journal of Biological Chemistry.
[27] W. Greene,et al. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. , 2003, Molecules and Cells.
[28] V. Pathak,et al. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[29] Gerhard Wagner,et al. A solubility-enhancement tag (SET) for NMR studies of poorly behaving proteins , 2001, Journal of biomolecular NMR.
[30] Xiaojun Wang,et al. Identification of a Critical T(Q/D/E)x5ADx2(I/L) Motif from Primate Lentivirus Vif Proteins That Regulate APOBEC3G and APOBEC3F Neutralizing Activity , 2010, Journal of Virology.
[31] A. Friedler,et al. Human immunodeficiency virus type 1 Vif‐derived peptides inhibit the viral protease and arrest virus production , 1998, FEBS letters.
[32] P. V. von Hippel,et al. Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.
[33] S. Bernacchi,et al. Tumultuous Relationship between the Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) and the Human APOBEC-3G and APOBEC-3F Restriction Factors , 2009, Microbiology and Molecular Biology Reviews.
[34] W. Greene,et al. HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. , 2010, Molecular aspects of medicine.
[35] Reuben S. Harris,et al. Retroviral restriction by APOBEC proteins , 2004, Nature Reviews Immunology.
[36] D. Trono,et al. A Single Amino Acid Determinant Governs the Species-specific Sensitivity of APOBEC3G to Vif Action* , 2004, Journal of Biological Chemistry.
[37] C. K. Grant,et al. The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells , 1997, Journal of virology.
[38] M. Marin,et al. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation , 2003, Nature Medicine.
[39] J. Goncalves,et al. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. , 2004, Genes & development.
[40] W. Blair,et al. High-Throughput Human Immunodeficiency Virus Type 1 (HIV-1) Full Replication Assay That Includes HIV-1 Vif as an Antiviral Target , 2005, Antimicrobial Agents and Chemotherapy.
[41] A. Friedler,et al. Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region. , 2002, The Journal of general virology.
[42] A. Gronenborn,et al. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain , 2009, Proceedings of the National Academy of Sciences.
[43] G. Manning,et al. Mutational Alteration of Human Immunodeficiency Virus Type 1 Vif Allows for Functional Interaction with Nonhuman Primate APOBEC3G , 2006, Journal of Virology.
[44] N. Landau,et al. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[45] J. Wedekind,et al. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. , 2003, Trends in genetics : TIG.
[46] M. Khan,et al. HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. , 2008, Virology.
[47] A. Friedler,et al. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors. , 1999, Journal of molecular biology.
[48] Jian-Dong Jiang,et al. Small Molecular Compounds Inhibit HIV-1 Replication through Specifically Stabilizing APOBEC3G* , 2010, The Journal of Biological Chemistry.
[49] HaroldC. Smith,et al. Retrovirology Open Access the Dimerization Domain of Hiv-1 Viral Infectivity Factor Vif Is Required to Block Virion Incorporation of Apobec3g , 2007 .
[50] M. Emerman,et al. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene , 1992, Journal of virology.
[51] Richard T D'Aquila,et al. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. , 2008, Virology.
[52] C. Tisné,et al. Advances in the structural understanding of Vif proteins. , 2008, Current HIV research.
[53] E. Thomas,et al. A Zinc-binding Region in Vif Binds Cul5 and Determines Cullin Selection* , 2006, Journal of Biological Chemistry.
[54] Hui Zhang,et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA , 2003, Nature.
[55] J. Wedekind,et al. The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[56] Y. Xiong,et al. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. , 2007, Journal of molecular biology.
[57] Gersende Caron,et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.
[58] Brent R. Martin,et al. Mammalian cell–based optimization of the biarsenical-binding tetracysteine motif for improved fluorescence and affinity , 2005, Nature Biotechnology.
[59] M. Malim,et al. Rationalisation of the Differences between APOBEC3G Structures from Crystallography and NMR Studies by Molecular Dynamics Simulations , 2010, PloS one.
[60] Erez Pery,et al. Regulation of APOBEC3 Proteins by a Novel YXXL Motif in Human Immunodeficiency Virus Type 1 Vif and Simian Immunodeficiency Virus SIVagm Vif , 2008, Journal of Virology.
[61] R. König,et al. Complementary function of the two catalytic domains of APOBEC3G. , 2005, Virology.
[62] C. Burrell,et al. The role of Vif during HIV-1 infection: interaction with novel host cellular factors. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[63] Mariana Santa-Marta,et al. HIV-1 Vif Can Directly Inhibit Apolipoprotein B mRNA-editing Enzyme Catalytic Polypeptide-like 3G-mediated Cytidine Deamination by Using a Single Amino Acid Interaction and Without Protein Degradation* , 2005, Journal of Biological Chemistry.
[64] B. Carlson,et al. Association of Human Immunodeficiency Virus Type 1 Vif with RNA and Its Role in Reverse Transcription , 2000, Journal of Virology.
[65] Xiaojiang S. Chen,et al. The current structural and functional understanding of APOBEC deaminases , 2009, Cellular and Molecular Life Sciences.
[66] Tomoki Yamashita,et al. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity. , 2010, Microbes and infection.
[67] Y. Xiong,et al. Structural Insight into the Human Immunodeficiency Virus Vif SOCS Box and Its Role in Human E3 Ubiquitin Ligase Assembly , 2008, Journal of Virology.
[68] Mark R. Sanderson,et al. The SOCS-Box of HIV-1 Vif Interacts with ElonginBC by Induced-Folding to Recruit Its Cul5-Containing Ubiquitin Ligase Complex , 2010, PLoS pathogens.
[69] V. Uversky,et al. Flexible Viruses: Structural Disorder in Viral Proteins , 2012 .
[70] Hong Cao,et al. Small-molecule inhibition of HIV-1 Vif , 2008, Nature Biotechnology.
[71] B. Strack,et al. Vif Overcomes the Innate Antiviral Activity of APOBEC3G by Promoting Its Degradation in the Ubiquitin-Proteasome Pathway* , 2004, Journal of Biological Chemistry.
[72] R. W. Davis,et al. Identification of 81LGxGxxIxW89 and 171EDRW174 Domains from Human Immunodeficiency Virus Type 1 Vif That Regulate APOBEC3G and APOBEC3F Neutralizing Activity , 2010, Journal of Virology.
[73] Shu Zheng,et al. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[74] Erez Pery,et al. Identification of an APOBEC3G Binding Site in Human Immunodeficiency Virus Type 1 Vif and Inhibitors of Vif-APOBEC3G Binding , 2007, Journal of Virology.
[75] Ryan C. Burdick,et al. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. , 2009, Trends in pharmacological sciences.
[76] L. Kleiman,et al. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. , 2008, Virology.
[77] Rodrigo Lopez,et al. Clustal W and Clustal X version 2.0 , 2007, Bioinform..